U,

I should add this:

Al:

"The last patient first visit for the 175 trial is also on track with the revised schedule, thus both trials are expected to be completed in the second quarter of next year with resubmission of the NDA in Q3."

http://seekingalpha.com/article/792571-mannkind-s-ceo-discusses-q2-2012-results-earnings-call-transcript?find=type%20II&all=false